Teva Pharma's most recent trend suggests a bullish bias. One trading opportunity on Teva Pharma is a Bull Put Spread using a strike $40.00 short put and a strike $35.00 long put offers a potential 5.93% return on risk over the next 10 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $40.00 by expiration. The full premium credit of $0.28 would be kept by the premium seller. The risk of $4.72 would be incurred if the stock dropped below the $35.00 long put strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Teva Pharma is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Teva Pharma is bearish.
The RSI indicator is below 20 which suggests that the stock is in oversold territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Teva Pharma
Why NuPathe, Galena Biopharma, and Bitauto Holdings Are Today's 3 Best Stocks
Wed, 08 Jan 2014 22:16:12 GMT
Motley Fool – Despite the S&P 500 ending lower for the fourth time in five days, NuPathe, Galena Biopharma, and Bitauto Holdings all rose by double-digits.
S&P 500 ends flat in wake of Fed minutes
Wed, 08 Jan 2014 21:55:38 GMT
Reuters – The S&P 500 finished nearly flat on Wednesday as equity indexes had a muted reaction to the minutes from the U.S. Federal Reserve's most recent meeting, while Micron's strong results helped buoy the Nasdaq. …
US STOCKS-S&P 500 ends flat in wake of Fed minutes
Wed, 08 Jan 2014 21:54:42 GMT
Reuters – UK Focus – The S&P 500 finished nearly flat on Wednesday as equity indexes had a muted reaction to the minutes from the U.S. Federal Reserve's most recent meeting, while Micron's strong results helped buoy the Nasdaq. …
Senesco Offers A New Approach To Cancer Treatment And Dr. Phillip Frost Is Now With The Company
Wed, 08 Jan 2014 19:24:16 GMT
Seeking Alpha – (Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.) Investment Overview
[$$] Teva Seeks to Top Endo's Bid for NuPathe
Wed, 08 Jan 2014 19:20:25 GMT
The Wall Street Journal – Teva Pharmaceutical has offered $149 million to buy NuPathe, a small drug developer, looking to top a previous bid from Endo Health Solutions.
Also on Market Tamer…
Follow Us on Facebook